Eton Pharmaceuticals, Inc.
ETON
$17.46
$0.372.17%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Eton Pharmaceuticals (ETON, $17.3) Stochastic Oscillator left the overbought zone on August 22, 2025
8/23/2025
-
Tickeron - Stocks
8/22/2025
-
Zolmax
8/21/2025
-
MarketBeat
8/21/2025
-
Ticker Report
8/21/2025
-
GuruFocus
8/20/2025
-
GuruFocus
8/20/2025
-
GuruFocus
8/20/2025
-
Globe Newswire
8/15/2025
-
Tickeron - Stocks
8/15/2025
-
MarketBeat
8/11/2025
-
Simply Wall St
8/10/2025
-
MarketBeat
8/8/2025
-
GuruFocus
8/8/2025
-
SeekingAlpha
8/8/2025
-
Seeking Alpha: Transcripts
8/8/2025
-
ETF Channel
8/8/2025
-
SeekingAlpha
8/8/2025
-
Seeking Alpha - Long Ideas
8/8/2025
-
GuruFocus
8/8/2025
-
TipRanks Financial Blog
8/8/2025
-
GuruFocus
8/7/2025
-
Zacks Investment Research
8/7/2025
-
Fool.com Headlines
8/7/2025
-
GuruFocus
8/7/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
847 787 7361
Address
21925 W. Field Parkway
Deer Park, IL 60010-7278
Deer Park, IL 60010-7278
Country
Year Founded
Business Description
Sector
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the...
more